Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platform In Diabetes
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Tue Oct 28, 3:16AM CDT
Big Picture Thesis: Since Afrezza's approval MannKind's (NASDAQ: MNKD ) shares have declined more than 50% as enthusiasm for their partnership with Sanofi-Aventis (NYSE: SNY ) has tempered enthusiasm for Afrezza's commercial prospects on concerns...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18), SNY: 46.35 (+0.50)